Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 16:23 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform...
April 29, 2025 06:00 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
April 08, 2025 16:30 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
February 12, 2025 16:15 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
January 14, 2025 17:25 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
December 02, 2024 17:22 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with...
November 12, 2024 17:00 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced...
September 04, 2024 18:42 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
August 09, 2024 16:15 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
July 29, 2024 08:30 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug delivery...